STOCK TITAN

Camp4 Therapeutics Corp. Stock Price, News & Analysis

CAMP Nasdaq

Welcome to our dedicated page for Camp4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on Camp4 Therapeutics stock.

CAMP4 Therapeutics Corporation (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. The CAMP news feed highlights how the company advances its antisense oligonucleotide (ASO) pipeline, progresses clinical and preclinical programs, and enters strategic collaborations.

Readers can follow CAMP4’s updates on its SYNGAP1-related disorders program, including announcements about GLP toxicology studies for CMP-SYNGAP-01, translational data in humanized mouse models and non-human primates, and plans for Phase 1/2 clinical trial applications. News items also cover the company’s Urea Cycle Disorders program and the CMP-CPS-001 (CMP-001) Phase 1 trial, where CAMP4 has reported safety and pharmacokinetics data from single and multiple ascending dose cohorts in healthy volunteers.

CAMP4’s news flow includes financial and corporate updates such as private placements, underwritten offerings of common stock, and use of proceeds to support development of its product candidates. The company also reports on strategic agreements, including a research, collaboration and license agreement with GSK to discover and develop ASO drug candidates for neurodegenerative and kidney disease indications using CAMP4’s RAP Platform.

In addition, CAMP4 issues press releases on scientific presentations at major meetings, corporate highlights, and inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this news page to review CAMP4’s reported milestones, research progress, and financing activities related to its regulatory RNA-targeting therapeutic strategy.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.17%
Tags
-
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced the release date of its fiscal 2023 fourth quarter and full-year financial results, set for April 27, 2023, after market close. The company will hold a conference call at 5:00 p.m. Eastern to discuss these results, accessible via a webcast on their Investor Relations page. Investors can dial in using the provided phone numbers for participation.

With over 10 million active edge devices and more than 275 patents, CalAmp continues to be a leader in telematics, offering solutions that help over 14,000 organizations improve operational efficiency and compliance. They are focused on enhancing asset tracking and visibility for clients worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences earnings
-
Rhea-AI Summary

CalAmp (Nasdaq: CAMP), a leading connected intelligence company, announced a restructuring plan aimed at reducing approximately 8% of its workforce to align better with its Software and Subscription Services (S&SS) business model. CEO Jeff Gardner emphasized that this decision, though difficult, is necessary to accelerate business model conversion and enhance profitability. The company assures that these reductions will not impact sales initiatives and are intended to support ongoing efforts to secure new customers globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced that its President and CEO, Jeff Gardner, along with CFO Jikun Kim and SVP of Finance Cindy Zhang, will participate in the 25th Annual Needham Growth Conference on January 10, 2023, at the Lotte New York Palace Hotel. They are set to present at 3:45 p.m. ET and will be available for investor meetings throughout the day. A live video webcast and archived presentation will be accessible on CalAmp's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
conferences
-
Rhea-AI Summary

CalAmp (CAMP) reported an 8% increase in total revenue to $78.9 million for Q3 FY2023, outperforming expectations due to improved supply and backlog shipment. Software and Subscription Services (S&SS) revenue rose 11% to $49.3 million, accounting for 62% of total revenue. The remaining performance obligations increased 20% to $252 million. Although gross margin declined to 33.7% due to higher component costs, the company expects improvements in Q4. A net loss reduced to $4.7 million from $7.5 million in the prior quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.74%
Tags
-
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) plans to release its fiscal 2023 third quarter financial results on December 20, 2022, after market close. A conference call will follow at 5:00 p.m. Eastern to discuss the results, accessible via a webcast on CalAmp's website. The call can also be joined by phone. The company boasts over 10 million active edge devices and 275+ patents, serving over 14,000 organizations globally in telematics solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
conferences earnings
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) announced that Jikun Kim will join the company as Senior Vice President and Chief Financial Officer effective January 9, 2023. Kim's extensive experience in financial leadership, including roles at Momentus, Formlabs, and EMCORE, positions him to drive CalAmp's growth in the telematics sector. Xiaolian Zhang will transition from Interim CFO to Senior Vice President, while Erik Schulz remains as Vice President. Kim emphasized the evolving telematics market's role in asset tracking in light of global supply chain challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
management
-
Rhea-AI Summary

CalAmp (NASDAQ: CAMP) reported a 13% increase in total consolidated revenue to $72.8 million for Q2 FY2023, with Software and Subscription Services contributing $44.5 million, or 61% of total revenue. Telematics Products also saw a 13% growth to $28.3 million. Adjusted EBITDA rose to $4.8 million, marking a 7% margin. Despite the growth, the company recorded a net loss of $7.5 million or $0.21 per share, and cash reserves decreased to $47.7 million.

The outlook for Q3 indicates expected low to mid-single-digit revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.84%
Tags
-
Rhea-AI Summary

Blackline Safety has appointed Jason W. Cohenour, former President and CEO of Sierra Wireless, to its Board of Directors. Cohenour brings over 30 years of leadership experience in IoT and mobile communications, having led Sierra Wireless in a successful turnaround that grew revenue by nearly 800% to over CAD $1 billion. His expertise is expected to significantly contribute to Blackline's growth as it continues to innovate in connected safety technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
management
Rhea-AI Summary

CalAmp (Nasdaq: CAMP) will release its fiscal 2023 second quarter financial results after market close on September 22, 2022. A conference call is scheduled for 5:00 p.m. Eastern to discuss the results, accessible via webcast or phone. CalAmp supports over 14,000 organizations globally, with over 10 million active devices and a strong patent portfolio of 275+ patents, underlining its leadership in telematics. For those interested, a replay of the call will be available for 90 days after.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences earnings

FAQ

What is the current stock price of Camp4 Therapeutics (CAMP)?

The current stock price of Camp4 Therapeutics (CAMP) is $4.2 as of March 6, 2026.

What is the market cap of Camp4 Therapeutics (CAMP)?

The market cap of Camp4 Therapeutics (CAMP) is approximately 238.1M.

CAMP Rankings

CAMP Stock Data

238.13M
42.94M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE

CAMP RSS Feed